EditorialThe HCV care continuum does not end with cure: A call to arms for the prevention of reinfection
Section snippets
Financial support
Dr. Sulkowski received support through a NIH mid-career mentor award, K24 DA034621 and R01DA16065. Dr. Falade-Nwulia was supported by a NIH Mentored Patient-Oriented Research Career Development Award K23 DA041294.
Conflict of interest
Dr. Falade-Nwulia has nothing to disclose. Dr. Sulkowski reports research grants and personal fees from AbbVie, personal fees from Cocrystal, research grants and personal fees from Gilead, research grants and personal fees from Janssen, research grants and personal fees from Merck, and personal fees from Trek.
Authors’ contributions
Dr. Falade-Nwulia wrote the first draft of the manuscript; Dr. Sulkowski provided critical revisions to the work and created the figure. Both authors approved the final submission.
References (14)
- et al.
Hepatitis C reinfection after sustained virological response
J Hepatol
(2016) - et al.
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe
J Hepatol
(2017) - World Health Organization: Draft global health sector strategy on viral hepatitis, 2016–2021 – The first of it’s kind,...
- et al.
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
Hepatology
(2013) - et al.
Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights
Clin Infect Dis
(2016) - et al.
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM
Aids
(2011) - et al.
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM
Aids
(2013)
Cited by (12)
Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis
2021, Gastroenterologia y HepatologiaCitation Excerpt :Nevertheless, the really special conditions of the population studied (HIV+, MSM, high risk STD) is a remarkable strength, in order to assess the efficacy of early health interventions in those patients. As other authors have described,19,21 we face a group of patients with risky sexual practices, often related to drug use, who have a high risk of contracting sexually transmitted diseases. In these patients, in addition to providing treatment for HCV and other STDs, we must keep them linked to the medical care system to preserve the effect of the cure and detect possible reinfections, implement behavioral interventions aimed at reducing damage and offer help in the addiction management.
An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages
2020, Journal of HepatologyCitation Excerpt :Therefore, to achieve the goal of elimination of hepatitis C infection in Egypt, the strategy of elimination needs to be increasingly directed towards case-finding through mass screening in rural communities to identify and treat those not yet aware of their diagnosis.10 A further issue has been the continued high rate of new infections, estimated at 2–6 cases per 1,000 (equivalent to at least 170,000 new cases) per year9 due to unsafe injection and health care practices,10 highlighting the need for concomitant effective awareness raising and education campaigns to prevent new infections.11 We developed a community-based outreach model (educate, test and treat) for the prevention, diagnosis and treatment of hepatitis C infection across villages in rural Egypt, but applicable to other high burden countries.
Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States
2023, Public Health ReportsSerum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C
2022, Nature CommunicationsMeeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics
2020, Journal of Viral Hepatitis